Radiation therapy in borderline resectable pancreatic cancer: A review

被引:4
|
作者
Turner, Kevin M. [1 ]
Delman, Aaron M. [1 ]
Kharofa, Jordan R. [2 ]
Smith, Milton T. [3 ]
Choe, Kyuran A. [4 ]
Olowokure, Olugbenga [5 ]
Wilson, Gregory C. [1 ,6 ]
Patel, Sameer H. [1 ,6 ]
Sohal, Davendra [5 ]
Ahmad, Syed A. [1 ,6 ,7 ]
机构
[1] Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH USA
[2] Univ Cincinnati, Dept Radiat Oncol, Coll Med, Cincinnati, OH USA
[3] Univ Cincinnati, Dept Internal Med, Div Digest Dis, Coll Med, Cincinnati, OH USA
[4] Univ Cincinnati, Dept Radiol, Coll Med, Cincinnati, OH USA
[5] Univ Cincinnati, Dept Internal Med, Div Hematol & Oncol, Coll Med, Cincinnati, OH USA
[6] Univ Cincinnati, Dept Surg, Div Surg Oncol, Coll Med, Cincinnati, OH USA
[7] Univ Cincinnati, Chief Div Surg Oncol, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA
关键词
PHASE-II TRIAL; INTENSITY-MODULATED RADIOTHERAPY; NEOADJUVANT THERAPY; DUCTAL ADENOCARCINOMA; PREOPERATIVE CHEMORADIATION; OPEN-LABEL; GEMCITABINE; CHEMOTHERAPY; CHEMORADIOTHERAPY; RESECTION;
D O I
10.1016/j.surg.2021.12.013
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Borderline resectable pancreatic cancer constitutes a complex clinical entity, presenting the clinician with a locally aggressive disease that has a proclivity for distant spread. The benefits of radiation therapy, such as improved local control and improved survival, have been questioned. In this review we seek to summarize the existing evidence on radiation therapy in borderline resectable pancreatic cancer and highlight future areas of research. Methods: A comprehensive review of PubMed for clinical studies reporting outcomes in borderline resectable pancreatic cancer was performed in June 2021, with an emphasis placed on prospective studies.Results: Radiologic "downstaging" in borderline resectable pancreatic cancer is a rare event, although some evidence shows increased clinical response to neoadjuvant chemotherapy over radiation therapy. Margin status seems to be equivalent between regimens that use neoadjuvant chemotherapy alone and regimens that include neoadjuvant radiation therapy. Local control in borderline resectable pancreatic cancer is likely improved with radiation therapy; however, the benefit of improved local control in a disease marked by systemic failure has been questioned. Although some studies have shown improved survival with radiation therapy, differences in the delivery and tolerance of chemotherapy between the neoadjuvant and adjuvant setting confound these results. When the evidence is evaluated as a whole, there is no clear survival benefit of radiation therapy in borderline resectable pancreatic cancer.Conclusion: Once considered a staple of therapy, the role of radiation therapy in borderline resectable pancreatic cancer is evolving as systemic therapy regimens continues to improve. Increased clinical understanding of disease phenotype and response are needed to accurately tailor therapy for individual patients and to improve outcomes in this complex patient population. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [31] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [32] Management of borderline resectable pancreatic cancer
    Amit Mahipal
    Jessica Frakes
    Sarah Hoffe
    Richard Kim
    [J]. World Journal of Gastrointestinal Oncology, 2015, (10) : 241 - 249
  • [33] Management of Borderline Resectable Pancreatic Cancer
    Katz, Matthew H. G.
    Crane, Christopher H.
    Varadhachary, Gauri
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2014, 24 (02) : 105 - 112
  • [34] Management of borderline resectable pancreatic cancer
    Mahipal, Amit
    Frakes, Jessica
    Hoffe, Sarah
    Kim, Richard
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (10) : 241 - 249
  • [35] Management of Borderline Resectable Pancreatic Cancer
    Toesca, Diego A. S.
    Koong, Amanda J.
    Poultsides, George A.
    Visser, Brendan C.
    Haraldsdottir, Sigurdis
    Koong, Albert C.
    Chang, Daniel T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1155 - 1174
  • [36] Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer
    Yabushita, Yasuhiro
    Matsuyama, Ryusei
    Miyake, Kentaro
    Homma, Yuki
    Kumamoto, Takafumi
    Misumi, Toshihiro
    Hata, Masaharu
    Yamanaka, Shoji
    Fujii, Satoshi
    Endo, Itaru
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (04) : 493 - 502
  • [37] Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated
    Chuong, Michael D.
    Springett, Gregory M.
    Freilich, Jessica M.
    Park, Catherine K.
    Weber, Jill M.
    Mellon, Eric A.
    Hodul, Pamela J.
    Malafa, Mokenge P.
    Meredith, Kenneth L.
    Hoffe, Sarah E.
    Shridhar, Ravi
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (03): : 516 - 522
  • [38] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    June S Peng
    Jane Wey
    Sricharan Chalikonda
    Daniela S Allende
    R Matthew Walsh
    Gareth Morris-Stiff
    [J]. Hepatobiliary & Pancreatic Diseases International, 2019, 18 (04) : 373 - 378
  • [39] Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
    Danko Mikulic
    Anna Mrzljak
    [J]. World Journal of Clinical Cases, 2021, 9 (20) : 5398 - 5407
  • [40] Multimodality Therapy for Borderline Resectable Pancreatic Cancer: A Single Institution Experience
    Pimiento, J. M.
    Hutchinson, T.
    Weber, J.
    Patel, M.
    Hodul, P. J.
    Chuong, M. D.
    Springett, G.
    Hoffe, S. E.
    Karl, R.
    Centeno, B.
    Klapman, J.
    Shridhar, R.
    Chen, D.
    Malafa, M. P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S10 - S10